Gabelli, M;
Ademokun, C;
Cooper, N;
Amrolia, PI;
(2022)
Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting.
British Journal of Haematology
, 196
(1)
pp. 45-62.
10.1111/bjh.17648.
Preview |
Text
Amrolia_Gabelli-AIHA post HSCT-reviewed manuscript-CLEAR-26.5.21.pdf - Accepted Version Download (247kB) | Preview |
![[thumbnail of Amrolia_Figure 1-Gabelli-17.3.21.jpg]](https://discovery.ucl.ac.uk/10133425/7/Amrolia_Figure%201-Gabelli-17.3.21.jpg)  Preview |
Image
Amrolia_Figure 1-Gabelli-17.3.21.jpg - Accepted Version Download (1MB) | Preview |
Preview |
Text
Amrolia_Figure 1- Gabelli-legend.pdf - Accepted Version Download (6kB) | Preview |
Preview |
Text
Amrolia_Gabelli- table I-AHIA post HSCT-24.5.21.pdf - Accepted Version Download (113kB) | Preview |
Preview |
Text
Amrolia_Gabelli- table II-24.5.21.pdf - Accepted Version Download (23kB) | Preview |
Preview |
Text
Amrolia_Gabelli-table III-24.5.21.pdf - Accepted Version Download (22kB) | Preview |
Preview |
Text
Amrolia_Gabelli-table IV-24.5.21.pdf - Accepted Version Download (60kB) | Preview |
Abstract
Autoimmune haemolytic anaemia (AIHA) is a rare complication of allogeneic haematopoietic stem cell transplantation (HSCT), observed with an incidence of 1–5%. Paediatric age, diagnosis of non-malignant disease, lympho-depleting agents in the conditioning regimen, use of unrelated donor, graft versus host disease and infections have been associated with a higher risk of AIHA post HSCT. Post-HSCT AIHA is associated with high mortality and morbidity, and it is often very difficult to treat. Steroids and rituximab are used with a response rate around 30–50%. These and other therapeutic strategies are mainly derived from data on primary AIHA, although response rates in post-HSCT AIHA have been generally lower. Here we review the currently available data on risk factors and therapeutic options. There is a need for prospective studies in post-HSCT AIHA to guide clinicians in managing these complex patients.
| Type: | Article |
|---|---|
| Title: | Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/bjh.17648 |
| Publisher version: | https://doi.org/10.1111/bjh.17648 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Autoimmune haemolytic anaemia, haematopoietic stem cell transplantation, autoimmunity, primary immunodeficiency, rituximab |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10133425 |
Archive Staff Only
 |
View Item |
